NASEM's 'Making Medicines Affordable' report assembled a big package of recommendations (8), implementing actions (27), and findings (18), but the committee passed over one idea that might be important for curative treatments in the future.
There are a lot of ideas and recommendations and different points of view in the National Academies of Science, Engineering and Medicine (NASEM) drug pricing report: “Making Medicines Affordable: A National Imperative.”
The report lists 18 “findings,” 8 broad recommendations, and no fewer than 27 implementing actions to address the affordability of prescriptions
Drugmakers are not expecting a big financial hit from tariffs for now, but a report commissioned by the industry trade association PhRMA suggests a potentially steep cost for pharma-sector tariffs.
The biotech CEO said the Trump Administration’s treatment of FDA employees, including the HHS secretary’s comments about industry capture, are insulting to agency staff, but he is encouraged by FDA Commissioner Martin Makary’s talk of a new conditional approval pathway.
Manufacturers are engaging the European Commission and individual countries to allocate more health care spending to innovative medicines and align prices more closely to those in the US.
